Oncolytics Biotech Investor Relations Material

Oncolytics Biotech Inc. (Oncolytics) is a development-stage biopharmaceutical company. The company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics' research and development activities are based on its proprietary lipid nanoparticle-laden virus, REOLYSIN. REOLYSIN is developed under Oncolytics' strategic alliance with BioCity Group Pty Ltd, an Australian government-backed translational research group focused on the improvement of cancer care via clinical and pharma applications for regenerative medicines. Oncolytics also has a license agreement with DaktariPharma UAB, a Lithuanian drug discovery company specializing in use of alternative medicine to treat cancer, for use of the oral formulation of cyclopamine in several European markets including Germany, France and Italy.